title: Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB.
abstract: Both clinical and preclinical research have shown that stress can potentiate drug use; however, the underlying mechanisms of this interaction are unknown. Previously, we have shown that a single exposure to forced swim (FS) reinstates extinguished conditioned place preference (CPP) to cocaine and that cAMP response element binding protein (CREB) is necessary for this response. CREB can be activated by corticotropin releasing factor (CRF) receptor type 1 (CRF(R1)) binding, which mediates neuroendocrine and behavioral responses to stress as well as to drugs of abuse. The present experiments investigate whether changes in cocaine reward elicited by previous exposure to stress are mediated by CREB and/or CRF(R1). Chronic exposure to FS in advance of conditioning enhances cocaine CPP in wild-type mice, but this is blocked in CREB-deficient mice. In addition, pretreatment with the CRF(R1) antagonist, antalarmin, before FS exposure blocks this stress-induced enhancement of cocaine CPP. Furthermore, FS-induced increase in phosphorylated CREB (pCREB), specifically in the lateral septum (LS) and nucleus accumbens (NAc) is also blocked by antalarmin. Taken together, these studies suggest that both CREB and CRF(R1) activation are necessary for stress-induced potentiation of drug reward.
authors.affiliation: Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104-3403, USA.
authors.forename: Arati S
authors.initials: AS
authors.lastname: Kreibich
authors.forename: Lisa
authors.initials: L
authors.lastname: Briand
authors.forename: Jessica N
authors.initials: JN
authors.lastname: Cleck
authors.forename: Laurel
authors.initials: L
authors.lastname: Ecke
authors.forename: Kenner C
authors.initials: KC
authors.lastname: Rice
authors.forename: Julie A
authors.initials: JA
authors.lastname: Blendy
mesh_terms: D000818:Animals; D003042:Cocaine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D009714:Nucleus Accumbens / Q000187:drug effects / Q000503:physiopathology; D010766:Phosphorylation / Q000187:drug effects / Q000502:physiology; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012201:Reward; D020665:Septum of Brain / Q000187:drug effects / Q000503:physiopathology; D013028:Space Perception / Q000187:drug effects / Q000502:physiology; D013315:Stress, Psychological / Q000503:physiopathology*; D013550:Swimming; D013997:Time Factors; D000099052:CRF Receptor, Type 1
chemical_list: C492004:Creb1 protein, mouse; D017362:Cyclic AMP Response Element-Binding Protein; D018765:Dopamine Uptake Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D018019:Receptors, Corticotropin-Releasing Hormone; C103016:antalarmin; D000099052:CRF Receptor, Type 1; D003042:Cocaine
references.citation: Neuroendocrinology. 1996 Nov;64(5):337-48
references.pmid: 8930934
references.citation: Psychopharmacology (Berl). 2003 Nov;170(2):124-31
references.pmid: 12845410
references.citation: Psychopharmacology (Berl). 1995 Jan;117(1):102-9
references.pmid: 7724693
references.citation: J Neurosci. 1992 Oct;12(10):4112-21
references.pmid: 1403102
references.citation: J Neurosci. 2008 Jul 9;28(28):7184-92
references.pmid: 18614688
references.citation: J Neurosci. 2008 Oct 29;28(44):11401-8
references.pmid: 18971482
references.citation: Psychopharmacology (Berl). 2005 Jul;180(2):215-23
references.pmid: 15696320
references.citation: Addict Behav. 1988;13(2):191-5
references.pmid: 3369329
references.citation: Psychopharmacology (Berl). 1996 Dec;128(3):256-64
references.pmid: 8972545
references.citation: Am J Psychiatry. 2007 Aug;164(8):1149-59
references.pmid: 17671276
references.citation: J Neurosci. 1993 Sep;13(9):3932-43
references.pmid: 8366353
references.citation: Psychopharmacology (Berl). 1994 Apr;114(3):523-7
references.pmid: 7855213
references.citation: Endocrinology. 1996 Dec;137(12):5747-50
references.pmid: 8940412
references.citation: Neuroimage. 2008 Jan 1;39(1):538-47
references.pmid: 17904386
references.citation: Curr Psychiatry Rep. 2007 Oct;9(5):388-95
references.pmid: 17915078
references.citation: Neuropharmacology. 2009;56 Suppl 1:122-32
references.pmid: 18675281
references.citation: Psychoneuroendocrinology. 1997 May;22(4):237-59
references.pmid: 9226728
references.citation: Ann N Y Acad Sci. 2002 Jun;966:119-30
references.pmid: 12114266
references.citation: Science. 1998 Dec 18;282(5397):2272-5
references.pmid: 9856954
references.citation: J Neuroendocrinol. 2002 Jul;14(7):587-92
references.pmid: 12121497
references.citation: J Health Soc Behav. 1986 Mar;27(1):44-61
references.pmid: 3486897
references.citation: J Neurosci. 2001 Dec 1;21(23):9438-44
references.pmid: 11717377
references.citation: Brain Res. 1993 Apr 16;608(2):216-22
references.pmid: 8495356
references.citation: J Neurosci. 2009 Feb 11;29(6):1855-9
references.pmid: 19211892
references.citation: Brain Res Brain Res Rev. 2004 Aug;46(1):71-117
references.pmid: 15297155
references.citation: J Neurosci. 2005 Jan 19;25(3):577-83
references.pmid: 15659593
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11435-40
references.pmid: 12165570
references.citation: Brain Res. 1990 Oct 29;531(1-2):322-8
references.pmid: 1963104
references.citation: J Pharmacol Exp Ther. 1997 Aug;282(2):967-76
references.pmid: 9262365
references.citation: Brain Res. 1995 Nov 6;698(1-2):46-52
references.pmid: 8581502
references.citation: Neuropsychopharmacology. 2000 Nov;23(5):577-86
references.pmid: 11027923
references.citation: Brain Res. 1990 Apr 23;514(1):22-6
references.pmid: 2357527
references.citation: J Neurosci. 2004 Jul 28;24(30):6686-92
references.pmid: 15282271
references.citation: Psychopharmacology (Berl). 1994 Feb;114(1):63-70
references.pmid: 7846208
references.citation: Neuropsychopharmacology. 2004 Jun;29(6):1122-33
references.pmid: 15029152
references.citation: J Neurosci. 2001 Sep 15;21(18):7397-403
references.pmid: 11549750
references.citation: Pharmacol Rev. 2001 Jun;53(2):209-43
references.pmid: 11356984
references.citation: J Stud Alcohol. 1992 Jul;53(4):357-63
references.pmid: 1619930
references.citation: Neurosci Biobehav Rev. 2004 Jan;27(8):765-76
references.pmid: 15019426
references.citation: Eur J Neurosci. 1999 Mar;11(3):997-1002
references.pmid: 10103093
references.citation: J Neurosci. 2002 Apr 15;22(8):3262-8
references.pmid: 11943827
references.citation: J Neurochem. 2003 Mar;84(6):1378-86
references.pmid: 12614338
references.citation: Neuroscience. 2006 Nov 3;142(4):1281-92
references.pmid: 16938401
references.citation: Behav Pharmacol. 1994 Jun;5(3):360-364
references.pmid: 11224287
references.citation: J Neurosci. 2003 Jul 2;23(13):5674-83
references.pmid: 12843270
references.citation: Eur J Neurosci. 2000 Jun;12(6):2097-106
references.pmid: 10886349
references.citation: Trends Pharmacol Sci. 1998 Feb;19(2):67-74
references.pmid: 9550944
references.citation: Psychopharmacology (Berl). 1979;66(1):87-91
references.pmid: 120547
references.citation: Neuron. 2005 Jun 16;46(6):933-43
references.pmid: 15953421
references.citation: Neuroscience. 2003;118(2):297-310
references.pmid: 12699766
references.citation: Drug Alcohol Depend. 1998 Dec 1;53(1):67-77
references.pmid: 10933341
references.citation: Brain Behav Evol. 1989;33(2-3):157-61
references.pmid: 2758295
references.citation: J Neurosci. 2002 Aug 15;22(16):7308-20
references.pmid: 12177226
references.citation: Science. 1981 Sep 18;213(4514):1394-7
references.pmid: 6267699